Skip to main content

Table 4 Univariate and multivariate analyses of the risk factors for GI/GU fistula and perforation

From: Gastrointestinal/genitourinary perforation and fistula formation with or without bevacizumab in patients with previously irradiated recurrent cervical cancer: a Korean multicenter retrospective study of the Gynecologic Oncology Research Investigators Collaboration (GORILLA) group (GORILLA-1001)

Variables

Univariate

Multivariate

HR

95% CI

P value

HR

95% CI

P value

Age

  < 50

1

  

1

  

  ≥ 50

0.577

0.278–1.197

0.140

0.666

0.307–1.445

0.304

DM

 No

1

     

 Yes

0.710

0.154–3.269

0.710

   

HTN

 No

1

  

1

  

 Yes

0.413

0.120–1.429

0.163

0.426

0.116–1.566

0.199

Diagnosis, year

      

 2007–2013

1

  

1

  

 2014–2020

1.624

0.697–3.781

0.261

0.885

0.317–2.469

0.815

Histology

 Non-SCC

1

     

 SCC

1.050

0.492–2.239

0.899

   

FIGO stage

 I-II

1

     

 III-IV

0.947

0.463–1.935

0.881

   

IMRT

 No

1

  

1

  

 Yes

1.513

0.737–3.108

0.259

1.136

0.498–2.592

0.761

RT

 Primary

1

     

 After 1st recur

0.974

0.347–2.733

0.960

   

Bevacizumab administration

 No

1

  

1

  

 Yes

3.026

1.199–7.640

0.019

3.273

1.177–9.096

0.023

  1. HR Hazard Ratio, CI Confidence Interval, DM Diabetes Mellitus, HTN Hypertension, SCC Squamous Cell Carcinoma, FIGO International Federation of Gynecology and Obstetrics, IMRT Intensity-modulated radiation therapy, RT Radiation Therapy